June 2020
Volume 61, Issue 7
ARVO Annual Meeting Abstract  |   June 2020
Longitudinal Assessment of Intraocular Cytokine Expression in Retinal Venous Occlusive Disease Following Anti-VEGF Therapy
Author Affiliations & Notes
  • sruthi arepalli
    Cole Eye Institute, Cleveland, Ohio, United States
  • Charles C. Wykoff
    Retina Consultants of Houston, TX, Texas, United States
  • Joseph R Abraham
    Cole Eye Institute, Cleveland, Ohio, United States
  • David M Brown
    Retina Consultants of Houston, TX, Texas, United States
  • Leina Lunasco
    Cole Eye Institute, Cleveland, Ohio, United States
  • Jamie Reese
    Cole Eye Institute, Cleveland, Ohio, United States
  • Justis P Ehlers
    Cole Eye Institute, Cleveland, Ohio, United States
  • Footnotes
    Commercial Relationships   sruthi arepalli, None; Charles C. Wykoff, Adverum (F), Alimera Sciences (C), Allegro (C), Allergan (F), Alynylam (C), Apellis (F), Bayer (C), Clearside (F), D.O.R.C (C), EyePoint (F), EyePoint (C), Genentech/Roc (F), Genentech/Roche (C), Kodiak (C), Neurotech (F), Notal Vision (C), Novartis (F), ONL Therapeutics (C), Opthea (F), PolyPhotonix (C), RecensMedical (C), Regeneron (F), Regenxbio (F), Samsung (F), Santen (F); Joseph Abraham, None; David Brown, Adverum (F), Allergan (F), Allergan (C), Apellis (F), Apellis (C), Bayer (C), Biotime (C), Chengdu Kanghong Biotechnology (C), Clearside (F), Gemini (C), Genentech/Roch (F), Genentech/Roche (C), Heidelberg (C), Novartis (F), Novartis (C), OHR (C), Opthea (F), Optos (C), Regeneron (F), Regeneron (C), Regenxbio (F), Samsung (F), Santen (F), Senju (C), Zeiss (C); Leina Lunasco, None; Jamie Reese, None; Justis Ehlers, Aerpio (F), Aerpio (C), Alcon (F), Alcon (C), Allegro (C), Allergan (F), Allergan (C), Genentech (F), Genentech/Roche (C), Leica (C), Leica (P), Novartis (F), Novartis (C), Regeneron (F), Regeneron (C), Santen (C), Thrombogenics/Oxurion (F), Thrombogenics/Oxurion (C), Zeiss (C)
  • Footnotes
    Support  RPB Unrestricted Grant to the Cole Eye Institute RPB1508DM, NIH K23-EY022947, Regeneron REGE1901JE
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 3300. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      sruthi arepalli, Charles C. Wykoff, Joseph R Abraham, David M Brown, Leina Lunasco, Jamie Reese, Justis P Ehlers; Longitudinal Assessment of Intraocular Cytokine Expression in Retinal Venous Occlusive Disease Following Anti-VEGF Therapy. Invest. Ophthalmol. Vis. Sci. 2020;61(7):3300.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Vascular endothelial growth factor (VEGF) is well established in the pathogenesis of ischemia and macular edema (ME) associated with retinal vein occlusion (RVO), but clinical response to anti-VEGF therapy is not universal. This study evaluates the longitudinal alterations in intraocular cytokine expression during anti-VEGF therapy in a prospective clinical trial setting.

Methods : The IMAGINE study is a post-hoc analysis of cytokine expression and imaging features in retinal vascular disease that includes the WAVE study cohort. The WAVE study was a prospective randomized trial evaluating ranibizumab monotherapy versus a combination ranibizumab and targeted retinal photocoagulation (TRP) to nonperfusion in 30 eyes with central, hemi- or branch retinal vein occlusions (CRVO, HRVO, BRVO). Aqueous samples were obtained at baseline and with every injection. Fifty-four cytokines associated with inflammation and angiogenesis, including VEGF, ANG1, G-CSF, IL-6, and TGF-alpha were measured in quadruplicate using 2 multi-plex arrays. Cytokine levels were also compared between monotherapy and combination therapy.

Results : Of the 30 eyes, 27 (90%) had sufficient samples. The mean age was 64 years. Twenty-one of 27 eyes (78%) were in the combination therapy group. At baseline, VEGF, ANGPTL4, IL-6 and leptin, FGF-4 and G-CSF were elevated. Compared to baseline, VEGF concentrations were significantly lower at month 4 (p=0.007) and trended towards a significant decline by month 9 (p=0.08). At month 4, FGF-4 and G-CSF were significantly decreased (p=0.02 and 0.04). ANGPTL4 showed a significant decline at month 9 (p=0.05). Additionally, VEGF levels decreased threefold with combination treatment versus monotherapy. Eyes with BRVO demonstrated higher expression levels of angiogenin and TGF-alpha compared to eyes with CRVO.

Conclusions : As novel therapies are integrated into RVO management, precision medicine in therapeutic selection may be critical to optimize outcomes. In this study, multiple cytokines are demonstrated to be elevated in eyes with RVO with variable modulation following anti-VEGF therapy. Multi-modal therapy resulted in greater reduction in VEGF burden. Future research will include correlation of imaging features with underlying cytokine expression for the exploratory assessment of imaging biomarkers.

This is a 2020 ARVO Annual Meeting abstract.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.